Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Tesamorelin: mechanism of action

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue studied for its ability to stimulate endogenous growth hormone secretion. This page outlines its mechanism of action and the research models in

peptides-pro Editorial

Tesamorelin: mechanism of action

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), also known as a GHRH analogue or GHRH receptor agonist. Its formal name is tesamorelin; synonyms include EGRIFTA WR and EGRIFTA. The evidence block does not provide sequence, formula, or molecular weight identifiers. The work described here centres on the GHRH receptor pathway and its downstream effects on endogenous growth hormone (GH) secretion and IGF-1.

Tesamorelin acts as a GHRH receptor agonist, binding to GHRH receptors on pituitary somatotroph cells to stimulate endogenous growth hormone release. This mechanism is distinct from exogenous GH administration, as it relies on the body's own pulsatile GH secretion. The resulting increase in GH drives hepatic IGF-1 production, which mediates many of the anabolic and metabolic effects observed in research settings.

Research Studies

Tesamorelin and physical function in HIV: the TRIUMPH trial

The TRIUMPH study is a two-site, double-blind, randomised controlled trial of 100 sedentary older adults (aged 50–80 years) living with HIV who are frail or at risk for frailty and have excess abdominal adiposity. Participants were randomised to receive tesamorelin or placebo as an adjunct to a home-based semisupervised exercise programme for 24 weeks, followed by a 24-week extension phase [1]. The trial's overall goal was to examine the combined effect of exercise and the GHRH analogue tesamorelin on physical function [1]. A separate ClinicalTrials.gov record for the same trial notes that people with HIV experience earlier impairments in physical function and more rapid development of frailty compared to the general population, and that exercise alone is less effective and difficult to sustain in this group [5]. The trial aimed to learn whether tesamorelin improves physical function and muscle health in adults with HIV when combined with exercise [5].

Tesamorelin and liver fat in fatty liver disease

A randomised, double-blind, placebo-controlled Phase II study evaluated whether daily subcutaneous tesamorelin reduces liver fat in adults with fatty liver disease. Participants received tesamorelin or matching placebo for 52 weeks, with standardised lifestyle counselling in both groups. Liver fat was quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring included glucose metrics and IGF-1 [2]. This study was conducted in adults with fatty liver disease, not specifically in people living with HIV.

Tesamorelin and liver fat and histology in HIV

Liver disease is a leading comorbidity of HIV infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30–40% of patients with HIV infection. Nonalcoholic steatohepatitis (NASH) is a more severe form of NAFLD in which increased liver fat is accompanied by inflammation, cellular damage, and fibrosis. NAFLD is most prevalent in patients who also have increased visceral adiposity, and HIV-infected individuals with increased visceral adiposity generally have decreased growth hormone secretion. Tesamorelin is a GHRH analogue that increases endogenous GH [8]. This study evaluated tesamorelin's effects on liver fat and histology in HIV [8].

Tesamorelin and cognition in aging HIV-infected persons

A Phase II trial tested whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, significantly improves memory and thinking in HIV [7]. The study population was aging HIV-infected persons [7].

Tesamorelin and functional outcomes after peripheral nerve injury

A clinical trial evaluated the efficacy of tesamorelin as a therapy for peripheral nerve injuries. The investigators hypothesised that treatment with tesamorelin would result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves. Patients with upper extremity nerve injuries were randomly assigned to receive either tesamorelin treatment or no treatment. Assessments for nerve regeneration, muscle function, and sensation were conducted every three months for a total of 12 months. Outcomes in patients receiving tesamorelin were compared to those in the untreated group to determine effectiveness [6].

Tesamorelin and HIV-associated lipodystrophy: systematic review and meta-analysis

A systematic review and meta-analysis evaluated the efficacy and safety of tesamorelin in people living with HIV (PLWH) with lipodystrophy receiving combined antiretroviral therapy (CART), incorporating GRADE assessment. The review searched PubMed, ClinicalTrials.gov, and Scopus from inception to February 9, 2026, for randomised controlled trials evaluating tesamorelin in HIV-associated lipodystrophy. Mean differences were calculated [3]. HIV-associated lipodystrophy, a complication of CART, causes significant physical and psychological distress in PLWH, compromising treatment adherence. Tesamorelin, a GHRH analogue, has emerged as a therapeutic option [3].

Tesamorelin and body composition, hepatic fat, and metabolic outcomes: meta-analysis

A meta-analysis of randomised controlled trials assessed body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy. HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks. The analysis assessed the effects of tesamorelin, a synthetic GHRH analogue that has been proposed as a treatment [10].

Tesamorelin and excess visceral abdominal fat: clinical cases

Two clinical cases highlighted distinct therapeutic pathways with tesamorelin and glucagon-like peptide-1 receptor agonists in people living with HIV-1 who have excess visceral abdominal fat (EVAF). EVAF is a prevalent metabolic complication among people living with HIV-1, occurring even in individuals with normal or mildly elevated body mass index (BMI). This pattern of fat accumulation is associated with metabolic dysfunction, cardiovascular risk, and other outcomes [9].

Tesamorelin formulations: bioequivalence in healthy participants

A study examined the bioequivalence of tesamorelin (EGRIFTA WR and EGRIFTA) formulations in healthy participants [4]. The evidence block does not provide further details on the study design or outcomes.

Tesamorelin in sports medicine and musculoskeletal injury: narrative reviews

Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancement; however, clinical adoption has outpaced high-quality evidence and regulatory consensus. A structured narrative review summarised contemporary human and translational evidence (January 1, 2020–) [11]. Another review noted that peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins, and that their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone rigorous approval processes, the review addressed approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance [12]. These reviews are reference-only and do not focus exclusively on tesamorelin.

If you are reading this for personal health reasons

The material described here is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp